Replimune Group (NASDAQ:REPL) Sets New 12-Month High – Here’s Why

Replimune Group, Inc. (NASDAQ:REPL) reached a new 52-week high during mid-day trading on Wednesday . The company traded as high as $14.14 and last traded at $13.65, with a volume of 4763199 shares. The stock had previously closed at $13.67.

More Replimune Group News

Here are the key news stories impacting Replimune Group this week:

• Positive Sentiment: $150 million financing strengthens Replimune’s balance sheet. The company priced an underwritten offering of 9,701,490 common shares and pre-funded warrants for another 2,736,340 shares at approximately $12.06 per share. Proceeds are expected to support development and commercialization of its oncolytic immunotherapies, including its FDA-approved melanoma treatment. Replimune Announces Pricing of $150 Million Underwritten Offering
• Positive Sentiment: Shares rose following the offering pricing. The market may be interpreting the capital raise as reducing near-term funding concerns and providing resources for product development and commercialization, although the offering is also dilutive. Replimune Shares Rise After Pricing of Offering
• Positive Sentiment: Regulatory progress remains a major catalyst. Replimune’s RP1 therapy received FDA approval for advanced melanoma, easing a significant regulatory uncertainty and expanding the company’s commercial opportunity. Why Replimune Stock Has Surged
• Neutral Sentiment: Analyst sentiment is mixed. One report cited a price-target increase to $20, but other recent ratings and targets have been considerably more cautious. This suggests substantial disagreement about the company’s valuation and commercial execution.
• Negative Sentiment: Several law firms publicized a securities-fraud class action against Replimune and certain officers. The lawsuit covers investors who purchased shares from October 20, 2025, through April 10, 2026, and alleges violations of federal securities laws. The announcements increase headline and potential legal risk, although the allegations have not been proven. Investors have until October 5, 2026, to seek lead-plaintiff status. Replimune Class Action Announcement
• Negative Sentiment: The equity offering will dilute existing shareholders. The issuance of more than 12.4 million shares and share-equivalent warrants increases the company’s share count, potentially limiting per-share upside despite improving liquidity.

Wall Street Analysts Forecast Growth

REPL has been the topic of a number of research reports. Wall Street Zen raised shares of Replimune Group from a “strong sell” rating to a “sell” rating in a research note on Saturday, May 23rd. Leerink Partners raised shares of Replimune Group from a “market perform” rating to an “outperform” rating and increased their price objective for the stock from $11.00 to $17.00 in a research report on Tuesday, August 4th. Piper Sandler upgraded shares of Replimune Group from a “hold” rating to a “strong-buy” rating in a report on Friday, July 31st. Wolfe Research upgraded shares of Replimune Group to an “outperform” rating in a report on Tuesday, August 4th. Finally, JPMorgan Chase & Co. boosted their price objective on shares of Replimune Group from $17.00 to $20.00 and gave the company an “overweight” rating in a research report on Friday, August 7th. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, two have given a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $11.86.

Replimune Group Stock Down 0.1%

The firm has a market capitalization of $1.15 billion, a P/E ratio of -4.04 and a beta of 0.88. The firm’s 50 day moving average is $10.34 and its two-hundred day moving average is $7.64. The company has a debt-to-equity ratio of 0.63, a current ratio of 4.79 and a quick ratio of 4.79.

Replimune Group (NASDAQ:REPL) last posted its quarterly earnings results on Monday, June 29th. The company reported ($0.76) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.66) by ($0.10). Research analysts predict that Replimune Group, Inc. will post -2.45 EPS for the current year.

Insider Buying and Selling at Replimune Group

In other news, insider Christopher Sarchi sold 12,000 shares of the company’s stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $9.24, for a total value of $110,880.00. Following the sale, the insider directly owned 180,962 shares of the company’s stock, valued at approximately $1,672,088.88. This represents a 6.22% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 5.40% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Replimune Group

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Ieq Capital LLC acquired a new position in Replimune Group during the second quarter worth approximately $908,000. Allworth Financial LP acquired a new stake in shares of Replimune Group in the second quarter valued at approximately $62,000. E Fund Management Co. Ltd. acquired a new stake in shares of Replimune Group in the second quarter valued at approximately $119,000. BlackRock Inc. bought a new position in shares of Replimune Group during the 2nd quarter worth approximately $99,171,000. Finally, Deutsche Bank AG bought a new position in shares of Replimune Group during the 2nd quarter worth approximately $857,000. Institutional investors own 92.53% of the company’s stock.

Replimune Group Company Profile

Replimune Group, Inc is a clinical‐stage biotechnology company focused on developing next‐generation oncolytic immunotherapies for the treatment of solid tumors. The company’s proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune’s lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.